1
2
3
4
5
Now Trending AAPL GS BAC GOOG C MCD JPM VZ ADBE T
If you think MYL is headed higher click
higher
If you think MYL is headed lower click
lower
Buying Dips

CAT
PBR
XLNX
HPQ
NFLX
GLD
QCOM
XRT
UPS
ABX
BAX
TYC
MRX
GENZ
PBRA
FAZ
CF
EWZ
TEVA
IR
Selling Rips

EWX
EMB
AAPL
GS
ADBE
BAC
AMZN
MRK
KO
IBM
JNJ
COV
RIMM
WY
XOM
ACE
BHP
CPB
ABT
AMGN
MYL

Premium Advice

MYL

Mylan Inc.

Recent Community Picks
JPM up
BCON up
PFE up
FSLR up
FCX up
ISF up
UAUA up
TZA up
NFLX up
AAPL up
STI up
GS up
GLD up
IBM up
ORCL up
SHLD up

Last Trade: 17.66
%Change: +0.51%
Volume Analysis
Average Volume: 6468370
Half Hour Run Rate: 497566
1 Minute Run Rate: 16585
Run Rate Based: 4278930
Current Volume: 1668923
MYL is currently neutral.
P/E: 71.13
Market Cap: 5.463B
52 Week High: 23.63
52 Week Low: 14.12
Next Year EPS: 1.93
Similar Stocks to MYL
WPI PRX FRX IPXL LCI
Twitter Updates: MYL
Ajpl56 Ajpl56
NASDAQ. After Hours Most Active: $INTC, $MU, $SYMC, $MYL, $STX, http://bit.ly/AzYaT #nasdaq
rpReply! RTRetweet!

Ajpl56 Ajpl56
NASDAQ After Hours Most Active: $INTC, $MU, $SYMC, $MYL, $STX, http://bit.ly/AzYaT #nasdaq
rpReply! RTRetweet!

M5_808 M5_808
RT @Nasdaq: After Hours Most Active: $INTC, $MU, $SYMC, $MYL, $STX, http://bit.ly/AzYaT #nasdaq
rpReply! RTRetweet!

TradersHuddle TradersHuddle
Mylan ($MYL): Most Active Calls At CBOE http://wibi.us/ckTKAv

MYL - Mylan Inc.

Chart PatternChart Pattern
Mylan Inc. (Mylan) and its subsidiaries comprise a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients (API). As of May 5, 2009, the Company held a 71.2% interest in Matrix Laboratories Limited (Matrix). Through Matrix, it manufactures and supplies API for its own products and pipeline, as well as for third parties. Mylan has three segments: the Generics Segment, the Matrix Segment and the Specialty Segment. Mylan markets more than 570 products to consumers in more than 140 countries. Mylan's products cover an array of therapeutic categories, and offer a range of dosage forms and delivery systems, including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products. On June 2, 2008, the Company acquired Merck KGaA's Central & Eastern Europe (CEE) generics businesses.